Publication | Closed Access
Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial
11
Citations
0
References
2023
Year
HepatologyDecompensated CirrhosisLiver PhysiologyPharmacologyLiverhope Efficacy TrialComplications Of CirrhosisHepatology InflammationPharmacotherapyLiver DiseaseHepatology FibrosisFatty Liver DiseaseMedicinePhase-3 Trial
No additional data available for this publication yet. Check back later!